Risk stratification and targeted antifungal prophylaxis for prevention of aspergillosis and other invasive mold infections after liver transplantation.
Antifungal prophylaxis has been proposed for liver transplant recipients at increased risk for invasive mold infection. Risk factors for invasive mold infection after liver transplantation were selected to divide recipients into 3 groups: (1) high risk-transplantation on hemodialysis or delay of hospital discharge beyond day 7 after transplantation because of allograft or renal insufficiency; (2) intermediate risk-retransplantation or transplantation for fulminant hepatic failure; (3) low risk-absence of conditions in groups 1 and 2. During an intervention period (February 1999-April 2001), prophylactic administration of a lipid complex of amphotericin (Abelcet) at 5 mg/kg intravenously every 24 to 48 hours was recommended for high-risk recipients. The frequency of mold infection was compared to that of a preintervention period (February 1998-January 1999) when antifungal prophylaxis was not provided. During the intervention period, invasive mold infection developed in 2 (6%) of 35 high-risk recipients, 0 of 28 intermediate-risk recipients, and 1 (0.5%) of 187 low-risk recipients. Overall, of 58 liver transplant recipients, 3 (5%) developed an invasive mold infection during the preintervention period, compared with 3 (1%) of 250 during the intervention period (P = 0.08). The only death from invasive mold infection occurred during the preintervention period. Rates of pulse corticosteroid treatment of rejection and cytomegalovirus infection were lower during the intervention period. In conclusion, readily identifiable patient characteristics can be used to stratify liver transplant recipients for risk of invasive mold infection. Antifungal prophylaxis given to high-risk recipients may provide cost-effective prevention of these infections.
Hellinger
Walter C
WC
Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL 32224, USA.
Bonatti
Hugo
H
Yao
Joseph D
JD
Alvarez
Salvador
S
Brumble
Lisa M
LM
Keating
Michael R
MR
Mendez
Julio C
JC
Kramer
David J
DJ
Dickson
Rolland C
RC
Harnois
Denise M
DM
Spivey
James R
JR
Hughes
Christopher B
CB
Nguyen
Justin H
JH
Steers
Jeffery L
JL
D000666:Amphotericin B / Q000627:therapeutic use; D019072:Antibiotic Prophylaxis / Q000379:methods*; D000935:Antifungal Agents / Q000008:administration & dosage*; D001228:Aspergillosis / Q000453:epidemiology / Q000517:prevention & control*; D015331:Cohort Studies; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection; D006085:Graft Survival; D006801:Humans; D016867:Immunocompromised Host; D016031:Liver Transplantation / Q000009:adverse effects* / Q000276:immunology / Q000379:methods; D008297:Male; D009894:Opportunistic Infections / Q000517:prevention & control; D011183:Postoperative Complications / Q000517:prevention & control; D011300:Preoperative Care / Q000379:methods; D011336:Probability; D012189:Retrospective Studies; D018570:Risk Assessment; D018709:Statistics, Nonparametric; D016896:Treatment Outcome
D000935:Antifungal Agents; D000666:Amphotericin B